



Clinical trial results:

A phase 3 extension trial of DELTA 1 and DELTA 2 to evaluate the long-term safety of a twice-daily treatment with delgocitinib cream 20 mg/g as needed for up to 36 weeks in adult subjects with chronic hand eczema (DELTA 3)

Summary

EudraCT number	2020-002962-15
Trial protocol	NL DE DK FR ES BE PL IT
Global end of trial date	18 September 2023

Results information

Result version number	v1 (current)
This version publication date	29 September 2024
First version publication date	29 September 2024

Trial information

Trial identification

Sponsor protocol code	LP0133-1403
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04949841
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	LEO Pharma A/S
Sponsor organisation address	Industriparken 55, Ballerup, Denmark, 2750
Public contact	Clinical Disclosure, LEO Pharma A/S, disclosure@leo-pharma.com
Scientific contact	Clinical Disclosure, LEO Pharma A/S, disclosure@leo-pharma.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	30 January 2024
Is this the analysis of the primary completion data?	Yes
Primary completion date	18 September 2023
Global end of trial reached?	Yes
Global end of trial date	18 September 2023
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the long-term safety of an as-needed treatment with twice-daily applications of delgocitinib cream 20 mg/g.

Protection of trial subjects:

The trial was conducted in accordance with the Declaration of Helsinki (2013) and International Council for Harmonization (ICH) Good Clinical Practice (GCP) (2016), including archiving of essential documents.

Background therapy:

Not applicable

Evidence for comparator:

Not applicable

Actual start date of recruitment	23 August 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 162
Country: Number of subjects enrolled	United Kingdom: 23
Country: Number of subjects enrolled	Netherlands: 16
Country: Number of subjects enrolled	Poland: 180
Country: Number of subjects enrolled	Spain: 58
Country: Number of subjects enrolled	Belgium: 19
Country: Number of subjects enrolled	Denmark: 20
Country: Number of subjects enrolled	France: 68
Country: Number of subjects enrolled	Germany: 215
Country: Number of subjects enrolled	Italy: 40
Worldwide total number of subjects	801
EEA total number of subjects	616

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37	0

wk	
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	735
From 65 to 84 years	65
85 years and over	1

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Subjects who completed one of the two phase 3 trials with delgocitinib cream 20 mg/g or cream vehicle (parent trials – Trial 1401 [2020-002960-30] or Trial 1402 [2020-002961-32]) could participate.

Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	As-needed treatment with delgocitinib
------------------	---------------------------------------

Arm description:

Subjects will be treated with delgocitinib cream 20 mg/g twice daily as needed.

Delgocitinib: Delgocitinib cream 20 mg/g

Arm type	Experimental
Investigational medicinal product name	Delgocitinib cream
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Cutaneous use

Dosage and administration details:

Delgocitinib cream 20 mg/g twice daily as needed

Number of subjects in period 1	As-needed treatment with delgocitinib
Started	801
Completed	664
Not completed	137
Adverse event, serious fatal	1
Consent withdrawn by subject	52
Adverse event, non-fatal	7
Pregnancy	4
Various reasons	9
Lost to follow-up	9
Lack of efficacy	55

Baseline characteristics

Reporting groups

Reporting group title	Overall study
-----------------------	---------------

Reporting group description: -

Reporting group values	Overall study	Total	
Number of subjects	801	801	
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	45.0		
standard deviation	± 14.4	-	
Gender categorical			
Units: Subjects			
Female	512	512	
Male	289	289	
Ethnicity			
Units: Subjects			
Hispanic or Latino	21	21	
Not Hispanic or Latino	752	752	
Unknown or Not Reported	28	28	

End points

End points reporting groups

Reporting group title	As-needed treatment with delgocitinib
Reporting group description: Subjects will be treated with delgocitinib cream 20 mg/g twice daily as needed. Delgocitinib: Delgocitinib cream 20 mg/g	

Primary: Number of treatment-emergent AEs from baseline up to Week 38

End point title	Number of treatment-emergent AEs from baseline up to Week 38 ^[1]
End point description: An AE will be considered treatment emergent if it started after the baseline visit.	
End point type	Primary
End point timeframe: From baseline to Week 38	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses have been specified for the primary end point as the endpoint investigated safety.

End point values	As-needed treatment with delgocitinib			
Subject group type	Reporting group			
Number of subjects analysed	801			
Units: events	1238			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with IGA-CHE score at each scheduled visit

End point title	Number of participants with IGA-CHE score at each scheduled visit
End point description: The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).	
End point type	Secondary
End point timeframe: From baseline up to Week 36	

End point values	As-needed treatment with delgocitinib			
Subject group type	Reporting group			
Number of subjects analysed	801			
Units: Number				
At baseline: 0-Clear	77			
At baseline: 1-Almost clear	83			
At baseline: 2-Mild	345			
At baseline: 3-Moderate	243			
At baseline: 4-Severe	53			
Week 4: 0-Clear	58			
Week 4: 1-Almost clear	76			
Week 4: 2-Mild	436			
Week 4: 3-Moderate	189			
Week 4: 4-Severe	28			
Week 8: 0-Clear	73			
Week 8: 1- Almost clear	82			
Week 8: 2-Mild	413			
Week 8: 3- Moderate	167			
Week 8: 4- Severe	25			
Week 12: 0- Clear	79			
Week 12: 1-Almost Clear	76			
Week 12: 2-Mild	414			
Week 12: 3- Moderate	152			
Week 12: 4- Severe	18			
Week 16: 0- Clear	79			
Week 16: 1- Almost clear	77			
Week 16: 2- Mild	407			
Week 16: 3- Moderate	147			
Week 16: 4- Severe	13			
Week 20: 0- Clear	72			
Week 20: 1- Almost clear	90			
Week 20: 2- Mild	401			
Week 20: 3- Moderate	123			
Week 20: 4- Severe	19			
Week 24: 0- Clear	65			
Week 24: 1- Almost clear	67			
Week 24: 2- Mild	415			
Week 24: 3- Moderate	118			
Week 24: 4- Severe	15			
Week 28: 0- Clear	68			
Week 28: 1- Almost clear	79			
Week 28: 2- Mild	408			
Week 28: 3- Moderate	109			
Week 28: 4- Severe	8			
Week 32: 0- Clear	71			
Week 32: 1- Almost clear	67			
Week 32: 2- Mild	395			
Week 32: 3- Moderate	118			
Week 32: 4- Severe	12			
Week 36: 0- Clear	115			

Week 36: 1- Almost clear	124			
Week 36: 2- Mild	300			
Week 36: 3- Moderate	111			
Week 36: 4- Severe	13			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with IGA-CHE score of 0 (clear) or 1 (almost clear) at each scheduled visit

End point title	Number of participants with IGA-CHE score of 0 (clear) or 1 (almost clear) at each scheduled visit
-----------------	--

End point description:

The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline up to Week 36

End point values	As-needed treatment with delgocitinib			
Subject group type	Reporting group			
Number of subjects analysed	801			
Units: participants				
Baseline	160			
Week 4	134			
Week 8	155			
Week 12	155			
Week 16	156			
Week 20	162			
Week 24	132			
Week 28	147			
Week 32	138			
Week 36	239			

Statistical analyses

No statistical analyses for this end point

Secondary: HECSI score at each scheduled visit

End point title	HECSI score at each scheduled visit
-----------------	-------------------------------------

End point description:

The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers [except fingertips], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score).

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline up to Week 36

End point values	As-needed treatment with delgocitinib			
Subject group type	Reporting group			
Number of subjects analysed	801			
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline	30.8 (± 36.5)			
Week 4	24.3 (± 27.2)			
Week 8	21.4 (± 25.3)			
Week 12	20.2 (± 23.9)			
Week 16	17.9 (± 21.1)			
Week 20	17.8 (± 22.5)			
Week 24	17.7 (± 19.6)			
Week 28	16.6 (± 19.0)			
Week 32	16.9 (± 20.0)			
Week 36	15.4 (± 20.6)			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with HECSI-75 at each scheduled visit

End point title	Number of participants with HECSI-75 at each scheduled visit
-----------------	--

End point description:

The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers [except fingertips], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score). HECSI-75 is defined as at least 75% improvement in HECSI score from parent trial baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline to Week 36

End point values	As-needed treatment with delgocitinib			
Subject group type	Reporting group			
Number of subjects analysed	801			
Units: participants				
At baseline	347			
Week 4	391			
Week 8	415			
Week 12	411			
Week 16	432			
Week 20	438			
Week 24	409			
Week 28	414			
Week 32	411			
Week 36	452			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with HECSI-90 at each scheduled visit

End point title	Number of participants with HECSI-90 at each scheduled visit
-----------------	--

End point description:

The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers [except fingertips], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score). HECSI-90 is defined as at least 90% improvement in HECSI score from parent trial baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline to Week 36

End point values	As-needed treatment with delgocitinib			
Subject group type	Reporting group			
Number of subjects analysed	801			
Units: participants				
At baseline	207			
Week 4	195			
Week 8	224			
Week 12	222			
Week 16	229			
Week 20	239			
Week 24	204			
Week 28	236			
Week 32	220			

Week 36	291			
---------	-----	--	--	--

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Week 0 to week 36

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.0
--------------------	------

Reporting groups

Reporting group title	As-needed treatment with delgocitinib
-----------------------	---------------------------------------

Reporting group description:

As-needed treatment with delgocitinib cream 20 mg/g (N=801)

Serious adverse events	As-needed treatment with delgocitinib		
Total subjects affected by serious adverse events			
subjects affected / exposed	27 / 801 (3.37%)		
number of deaths (all causes)	3		
number of deaths resulting from adverse events	2		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Intraductal proliferative breast lesion			
subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lipofibroma			
subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Oesophageal cancer metastatic			
subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		

Pyogenic granuloma			
subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Death			
subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Immune system disorders			
Contrast media allergy			
subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Adnexal torsion			
subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Bronchiectasis			
subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Alcoholism			
subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			

Femur fracture			
subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Post procedural haemorrhage			
subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Myocardial infarction			
subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Nervous system disorders			
Facial paralysis			
subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal incarcerated hernia			
subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Abdominal pain upper			
subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Food poisoning			
subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Cholecystitis			

subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cholelithiasis			
subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Hand dermatitis			
subjects affected / exposed	2 / 801 (0.25%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Osteoarthritis			
subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Appendicitis			
subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Chronic sinusitis			

subjects affected / exposed	1 / 801 (0.12%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Complicated appendicitis				
subjects affected / exposed	1 / 801 (0.12%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Lower respiratory tract infection				
subjects affected / exposed	1 / 801 (0.12%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Paranasal sinus abscess				
subjects affected / exposed	1 / 801 (0.12%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Peritonsillar abscess				
subjects affected / exposed	1 / 801 (0.12%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pneumonia				
subjects affected / exposed	1 / 801 (0.12%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pyelonephritis				
subjects affected / exposed	1 / 801 (0.12%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Sinusitis aspergillus				
subjects affected / exposed	1 / 801 (0.12%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Urinary tract infection				

subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	1 / 801 (0.12%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 2 %

Non-serious adverse events	As-needed treatment with delgocitinib		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	329 / 801 (41.07%)		
Nervous system disorders			
Headache			
subjects affected / exposed	22 / 801 (2.75%)		
occurrences (all)	27		
Skin and subcutaneous tissue disorders			
Eczema			
subjects affected / exposed	17 / 801 (2.12%)		
occurrences (all)	21		
Hand dermatitis			
subjects affected / exposed	30 / 801 (3.75%)		
occurrences (all)	34		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	19 / 801 (2.37%)		
occurrences (all)	20		
Infections and infestations			
COVID-19			
subjects affected / exposed	134 / 801 (16.73%)		
occurrences (all)	138		
Influenza			

subjects affected / exposed	28 / 801 (3.50%)		
occurrences (all)	28		
Nasopharyngitis			
subjects affected / exposed	128 / 801 (15.98%)		
occurrences (all)	161		
Upper respiratory tract infection			
subjects affected / exposed	32 / 801 (4.00%)		
occurrences (all)	36		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
23 August 2021	This amendment was written to comply with requests from health authorities, to accommodate for the conduct of the trial in Russia, to add photography of hands at certain visits, and to proceed with administrative and editorial changes.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported